Drug-induced pleural disease

Clinics in Chest Medicine

Volumn 25, Issue 1, 2004, Pages 141-153

  Huggins, John T ^a   Sahn, Steven A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALCOHOL; ALPHA INTERFERON; AMIODARONE; BLEOMYCIN; BROMOCRIPTINE; CAPTOPRIL; CORTICOSTEROID; DANAZOL; GRISEOFULVIN; IBUPROFEN; LEUPRORELIN; LEVODOPA; LITHIUM CARBONATE; METHOTREXATE; METHYSERGIDE; MEVINOLIN; MINOXIDIL; MORRHUATE SODIUM; NALIDIXIC ACID; OXPRENOLOL; PRACTOLOL; PROCARBAZINE; PROMETHAZINE; SPIRONOLACTONE; STREPTOMYCIN; SULINDAC; THIAMAZOLE; TOLMETIN; UNINDEXED DRUG;

ACNE; AGRANULOCYTOSIS; ALOPECIA; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST TENDERNESS; CHEILITIS; CONGESTIVE HEART FAILURE; COUGHING; DERMATITIS; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EFFUSION; EMPYEMA; ENDOSCOPIC SCLEROTHERAPY; EOSINOPHILIA; EOSINOPHILIA MYALGIA SYNDROME; EPILEPSY; ESOPHAGUS VARICES; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TUMOR; GOODPASTURE SYNDROME; GRAVES DISEASE; HAIR DISEASE; HEAD AND NECK CARCINOMA; HEARING IMPAIRMENT; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEMOLYTIC ANEMIA; HEMOPTYSIS; HEPATITIS; HERPES VIRUS INFECTION; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; LUNG INFILTRATE; LUNG TOXICITY; LUPUS ERYTHEMATOSUS; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINITIS; MIGRAINE; MUCOSA INFLAMMATION; MYASTHENIA GRAVIS; NAUSEA; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREATITIS; PEMPHIGUS; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PLEURA BIOPSY; PLEURA DISEASE; PLEURA EFFUSION; PLEURA FLUID; PLEURA THICKENING; PLEURAL FIBROSIS; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PULMONARY HYPERTENSION; RASH; RESPIRATORY DISTRESS SYNDROME; RETROPERITONEAL FIBROSIS; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SCLEROSING PERITONITIS; SEDATION; SEIZURE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TESTIS CARCINOMA; THORACOCENTESIS; THORAX PAIN; THROMBOCYTOPENIA; URINARY TRACT INFECTION; URTICARIA; VALVULAR HEART DISEASE; WILSON DISEASE;

ANTI-INFECTIVE AGENTS, URINARY; ANTIMETABOLITES, ANTINEOPLASTIC; BLEOMYCIN; CARDIOVASCULAR AGENTS; CLOZAPINE; CYCLOPHOSPHAMIDE; EOSINOPHILIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; METHOTREXATE; METHYSERGIDE; NITROFURANTOIN; PENICILLAMINE; PLEURAL DISEASES; PLEURAL EFFUSION; SEROTONIN ANTAGONISTS;

EID: 1542302707     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00125-4     Document Type: Review

References (110)

1. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part I: cytotoxic drugs. Part II: non-cytotoxic drugs. Am Rev Respir Dis 1986;133:488-505.
2. Antony VB. Drug-induced pleural disease. Clin Chest Med 1998;19:331-40.
3. Morelock SY, Sahn SA. Drugs and the pleura. Chest 1999;116:212-21.
4. Sifton DW. The physicians desk reference. Montvale (NJ): Medical Economics Co.; 2003.
5. Martin WB, Spodick DH, Zins GR. Pericardial disorders during open-label study of 1,869 severely hypertensive patients treated with minoxidil. J Cardiovasc Pharmacol 1980;2(Suppl 2):S217-27.
6. Webb DB, Whale RJ. Pleuropericardial effusion associated with minoxidil administration. Postgrad Med J 1982;58:319-20.
7. Erwteman TM, Braat MC, Van Aken WG. Interstitial pulmonary fibrosis: a new side effect of practolol. BMJ 1977;2:297-8.
8. Dyer NH, Varley CC. Practolol-induced pleurisy and constrictive pericarditis. BMJ 1975;2:443.
9. Hall DR, Morrison JB, Edwards FR. Pleural fibrosis after practolol therapy. Thorax 1978;33:822-4.
10. Fleming HA, Hickling P. Pleural effusion after practolol. Lancet 1974;2:1202.
11. MacKay AD, Axford AT. Pleural effusions after practolol. Lancet 1976;2:1202.
12. Nicholls JT. Adverse effects of practolol. Ann Clin Res 1976;8:229-31.
13. Marshall AJ, Ettingham WK, Barritt DW, Griffiths DA, Davies JD, Jackson LK, et al. Respiratory disease associated with practolol therapy. Lancet 1977;2:1254-7.
14. Page RL. Progressive pleural thickening during oxprenolol therapy. Br J Dis Chest 1979;73:195-9.
15. Leech JA, Gallastegni J, Swiryn S. Pulmonary toxicity of amiodarone. Chest 1984;85:444-5.
16. Kuhlman JE, Teigen C, Ren H, Hruban RH, Hutchins GM, Fishman EK, et al. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology 1990;177:121-5.
17. Gonzalez-Rothi RJ, Hannan SE, Hood I, Franzini DA. Amiodarone pulmonary toxicity presenting as bilateral exudative pleural effusions. Chest 1987;92:179-82.
18. Clarke B, Ward DE, Honey M. Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. Int J Cardiol 1985;8:81-8.
19. Darmanata JI, van Zandwijk N, Daren DR, van Royen EA, Mooi WJ, Ploomp TA, et al. Amiodarone pneumonitis: three further cases with a review of published reports. Thorax 1984;34:57-64.
20. Gefter WB, Epstein DM, Pietra GG, Miller WT. Lung disease caused by amiodarone, a new antiarrhythmic agent. Radiology 1983;147:339-44.
21. Manolis AS, Tordjman T, Mack KD, Estes NA. Atypical pulmonary and neurological complications of amiodarone in the same patient. Arch Intern Med 1987;147:1805-9.
22. Marchlinski FE, Gansler TS, Waxman HL, Josephson ME. Amiodarone pulmonary toxicity. Ann Intern Med 1982;97:839-45.
23. Olson LK, Forrest JV, Friedman PJ, Kiser PE, Henschke CL. Pneumonitis after amiodarone therapy. Radiology 1984;150:329-30.
24. Rakita L, Sabol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. Am Heart J 1983;106:906-15.
25. Sabol SM, Rakita L. Pneumonitits and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation 1982;65:819-24.
26. Standertskjold CG, Wandkte JC, Hood Jr WB, et al. Amiodarone pulmonary toxicity: chest radiography and CT in asymptomatic patients. Chest 1985;88:143-5.
27. Stein B, Zaatari GS, Pine JR. Amiodarone pulmonary toxicity. Acta Cytol 1987;31:357-61.
28. Wood DL, Osborn MJ, Rooke J, Holmes Jr DR. Amiodarone pulmonary toxicity: report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography. Mayo Clin Proc 1985;60:601-3.
29. Zaher C, Hamer A, Peter T, Mandel W. Low-dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates. N Engl J Med. 1983;308:779.
30. Parikh SS, Amarapurkar DN, Dhawan PS, Kalro RH, Desai HG. Development of pleural effusion after sclerotherapy with absolute alcohol. Gastrointest Endosc 1993;39:404-5.
31. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967;254:1-12.
32. Graham JR, Suby HI, LeCompte MD, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966;274:359-68.
33. Bays RP. Pleuropulmonary fibrosis following therapy with methysergide maleate: two case reports. J LA State Med Soc 1968;120:436-7.
34. Dunn JM, Sloan H. Pleural effusions and fibrosis secondary to sansert administration. Ann Thorac Surg 1973;15:295-8.
35. Kok-Jenson A, Lindeneg O. Pleurisy and fibrosis of the pleura during methysergide treatment of hemicrania. Scand J Respir Dis 1970;51:218-22.
36. Hindle W, Posner E, Sweatnam MT, Tan RH. Pleural effusion and fibrosis during the treatment with methysergide. BMJ 1970;1:605-6.
37. Gefter WB, Epstein DM, Bonavita JA, Miller WT. Pleural thickening caused by sansert and ergotrate in the treatment of migraine. AJR 1980;135:375-7.
38. Boucek RJ, Alverez TR. Increase in survival of subcultured fibroblasts mediated by serotonin. Nature 1971;229:61-2.
39. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981;1:44.
40. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988;148:2231-6.
41. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30:613-6.
42. Frans E, Dom R, Demedts M. Pleuropulmonary changes during the treatment of Parkinson's disease with long-acting ergot derivative, cabergoline. Eur Respir J 1992;5:263-5.
43. Kinnunen E, Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. Chest 1988;94:1034-6.
44. LeWitt PA, Calne DB. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981;1:44-5.
45. Pascual RS, Mosher MB, Sikand RS, Deconti RC, Bouhuys AS. Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis 1973;108:211-7.
46. Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 1983;74:557-63.
47. Goldiner PL, Carlon GC, Cvitkovic E, Schweizer O, Houland WS. Factors influencing postoperative morbidity in patients treated with bleomycin. BMJ. 1978;1:1664-7.
48. Holoye PY, Luna MA, MacKay B, Bedrossian CM. Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978;88:47-9.
49. Jones S.E., Moore M., Blank N., Castellino R.A. Hypersensitivity to procarbazine manifested by fever and pleuropulmonary reaction. Cancer. 29:1972;498-500.
50. Farney RJ, Morris AH, Armstrong JD, Hammer S. Diffuse pulmonary disease after nitrogen mustard, vincristine, procarbazine, and prednisone. Am Rev Respir Dis 1977;115:135-45.
51. Ecker MD, Jay B, Keohane MF. Procarbazine lung. AJR 1978;131:527-8.
52. Abu-Shakra M, Nicol P, Urowitz MB. Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy. J Rheumatol 1994;21:934-7.
53. Sostman HD, Matthay RA, Putmant CE, Smith GJ. Methotrexate-induced pneumonitis. Medicine 1976;55:371-88.
54. Everts CS, Westscott JL, Brag DG. Methotrexate therapy and pulmonary disease. Radiology 1973;107:539-43.
55. Walden PA, Michell-Weggs PF, Coppin C, Dent J, Bagshane KD. Pleurisy and methotrexate treatment. BMJ 1972;2:867.
56. Schwartz IR, Kajani MK. Methotrexate therapy and pulmonary disease. JAMA 1969;210:1924.
57. Goldman GC, Moschella SL. Severe pneumonitis occurring during methotrexate therapy: report of two cases. Arch Dermatol 1971;103:194-7.
58. Orwoll RS, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med 1978;89:352-5.
59. Gunstream SR, Seidenfeld JJ, Sobonya RE, McMahon LJ. Mitomycin- associated lung diseases. Cancer Treat Rep 1983;67:301-4.
60. Ozols RF, Hocan WM, Ostchega Y, Young RC. MVP (mitomycin, vinblastine, and progesterone): a second line regimen in ovarian cancer with a high incidence of pulmonary toxicity. Cancer Treat Rep 1983;67:721-2.
61. Andre R, Rochant H, Dreyfus B, Duhamel G, Pechere JC. Fibrose interstitelle diffuse du poumon au cours d'une maladie de Hodgkin traitee par des doses elevees d'endoxan [Diffuse interstitial fibrosis of the lung in Hodgkin's disease treated by high doses of endoxan]. Bull Soc Med 1967;118:1133-41 [in French].
62. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Am J Respir Crit Care Med 1996;154:1851-6.
63. Maxwell I. Reversible pulmonary edema following cyclophosphamide treatment. JAMA 1974;229:137-8.
64. Alvarado CS, Boat TF, Newman AJ. Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide. J Pediatr 1978;92:443-6.
65. Abdel Karim FW, Ayash RE, Allam C, Salem PA. Pulmonary fibrosis after prolonged treatment with low dose cyclophosphamide. Oncology 1983;40:174-6.
66. Schaap N, Raymakers R, Schattenberg A, Ottevanger JP, DeWitte T. Massive pleural effusion attributed to high-dose cyclophosphamide during conditioning for BMT. Bone Marrow Transplant 1996;18:247-8.
67. Wohlrab JL, Liu MC, Anderson ED, Kia Noury DB, Read CA, Warren RD. Docetaxel induced pleural effusions [abstract]. Chest 2002;122:94S-5S.
68. Sahn SA. The diagnostic value of pleural fluid analysis. Semin Respir Crit Care Med 1995;16:269-78.
69. Kaufman J. Eosinophilic pleural effusions associated with valproic acid administration. South Med J 1996;88:881-2.
70. Middleton KL, Santella R, Couser Jr JI. Eosinophilic pleuritis due to propylthiouracil. Chest 1993;103:955-6.
71. Milleron BJ, Valcke J, Akoun GM, Mayaud CM. Isotretinoin-related eosinophilic pleural effusion. [letter] Chest 1996;110:1128.
72. Bunker CB, Sheron N, Maurice PD, Kocjan G, Johnson NM, Dowd PM. Isotretinoin and eosinophilic pleural effusion. Lancet 1989;1:435-6.
73. Larsson S, Cronberg S, Denneberg T, Ohlsson NM. Pulmonary reactions to nitrofurantoin. Scand J Respir Dis 1973;54:103-10.
74. Israel HL, Diamond P. Recurrent pulmonary infiltration and pleural effusion due to nitrofurantion sensitivity. N Engl J Med 1962;266:1024-6.
75. Rosenow III EC. Drug-induced bronchopulmonary pleural disease. J Allergy Clin Immunol 1987;80:780-7.
76. Rosenow III EC, DeRemee RA, Dines DE. Chronic nitrofurantoin pulmonary reactions: report of five cases. N Engl J Med 1968;279:1258-62.
77. Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin: 447 cases reported to the Swedish adverse drug reaction committee. Eur J Respir Dis 1981;62:180-9.
78. Geller M, Flaherty DK, Dickie HA, Reed CE. Lymphopenia in acute nitrofurantoin pleuropulmonary disease. J Allergy Clin Immunol 1977;49:445-8.
79. Petusevsky ML, Faling LJ, Rocklin RE, Snider GL, Merliss AD, Moses JM, et al. Pleuropericardial reaction to treatment with dantrolene. JAMA 1979;242:2772-4.
80. Mahoney JM, Bachtel MD. Pleural effusion associated with chronic dantrolene administration. Ann Pharmacother 1994;28:587-9.
81. Miller DH, Haas LF. Pneumonitis, pleural effusion, and pericarditis following treatment with dantrolene administration. J Neurol Neurosurg Psychiatry 1984;47:553-4.
82. Clarysse AM, Cathey WJ. Dantrolene sodium: longterm effects in severe spasticity. Arch Phys Med Rehabil 1973;54:311-5.
83. Tzanakis N, Bouros D, Siarakas N. Eosinophilic pleural effusion associated due to gliclazide. Resp Med 2000;94:94.
84. Pusateri DW, Muder RR. Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for Herpes zoster ophthalmicus. Chest 1990;98:754-6.
85. Daly JM, Godber RJ, Braman SS. Polyserositis associated with clozapine treatment. Am J Psychiatry 1992;149:1274-5.
86. ChatterjeeA, Safferman A. Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment. J Clin Psychopharmacol 1997;17:232-3.
87. Thompson J, Chengappa KNR, Good CB, Baker RW, Kiese RP, Bezner J, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Inter Clin Psychopharmacol 1998;13:95-8.
88. Sternlieb I, Bennett B, Scheinberg IH. D-penicillamine induced Goodpasture's syndrome in Wilson's disease. Ann Intern Med 1975;82:673-6.
89. Karkos C, Moore A, Manche A, Thorpe JA. Pleural effusion associated with D-penicillamine therapy: a case report. J Clin Pharm Ther 1996;21:15-7.
90. Busmanis IA, Beaty AE, Basser RL. Isolated pleural effusion with hematopoietic cells of mixed lineage in a patient receiving granulocyte-colony- stimulating factor after high-dose chemotherapy. Diagn Cytopathol 1998;18:204-7.
91. Vogelzang PJ, Bloom SM, Mier JW, Atkins MB. Chest roentgenography abnormalities in IL-2 recipients: incidence in correlation with clinical parameters. Chest 1992;101:746-52.
92. Saxon RR, Klein JR, Bar MH, Blanc P, Gamso G, Webb WR, et al. Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings of 54 patients. Am J Roentgenol 1991;156:281-5.
93. Gunther J, Lode H, Raffenberg M, Schaberg T. Development of pleural and pericardial effusions during itraconazole therapy for pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis 1993;12:723-4.
94. Belongia EA, Hedberg CW, Gleich GJ, White E, Mayeno AN, Loegering DA, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357-65.
95. Martin RW, Duffy J, Engel AG, Lie JT, Bowles CA, Moyer TP, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Ann Intern Med 1990;113:124-34.
96. Shore ET. L -tryptophan induced cough and pleural effusion associated with the eosinophilia-myalgia syndrome. Chest 1990;98:1540.
97. Strumpf IF, Drucker RD, Anders KH, Cohen S, Fajolu O. Acute eosinophilic pulmonary disease associated with the ingestion of -tryptophan containing products. Chest 1991;99:8-13.
98. Travis WD, Kalafer ME, Robin HS, Luibel FJ. Hypersensitivity pneumonitis and pulmonary vasculitis with eosinophilia in a patient taking an L -tryptophan preparation. Ann Intern Med 1990;112:301-3.
99. Gujral N, Friedenberg F, Friedenberg J, Gabriel G, Kotler M, Levine G. Pleuropericarditis related to the use of mesalamine. Dig Dis Sci 1996;41:624-6.
100. Trisolini R, Dore R, Biagi F, Luinetti O, Pochetti P, Carrabino N, et al. Eosinophilic pleural effusion due to mesalamine. Report of a rare occurrence. Sarcoidosis Vasc Diffuse 2000;17:288-91.
101. De Groot RE, Willems LN, Dijkman JH. Interstitial lung disease with pleural effusion caused by simvastin. J Intern Med 1996;239:361-3.
102. Koshida H, Shibata K, Kametani T. Pleuropulmonary disease in a man with diabetes who was treated with troglitazone. N Engl J Med 1998;339:1400-1.
103. Bolanos-Meade J, Keung YK, Cobos E. Recurrent lymphocytic pleural effusion after intravenous immunoglobulin. Am J Hematol 1999;60:248-9.
104. Hoffman BJ. Sensitivity of sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph 1945;51:190-2.
105. Yung YL, Richardson BC. Drug-induced lupus. Rheum Dis Clin N Amer 1994;20:61-85.
106. Good JT, King TE, Antony VB, Sahn SA. Lupus pleuritis: clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibody titers. Chest 1983;84:714-5.
107. Henningsen NC, Cederberg A, Hanson A, Johansson BW. Effects of long-term treatment with procainamide: a prospective study with special regard to ANF and SLE in fast and slow acetylators. Acta Med Scand 1975;198:475-82.
108. Woosley RL, Drayer DE, Reidberg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies in the lupus syndrome. N Engl J Med 1978;298:1157-9.
109. Cush JJ, Goldings EA. Drug-induced lupus: clinical spectrum and pathogenesis. Am J Med Sci 1985;290:36-45.
110. Burlingame LW, Ruben RL. Drug-induced anti-histone antibodies displayed two patterns of reactivity with substructures of chromatin. J Clin Invest 1991;88:860-90.